• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

    23.84 +0.95 (+4.15%)
    Streaming Delayed Price Updated: 1:57 PM EDT, Jul 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Syndax Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    News headline image
    Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Stock Slides After Q1 Revenue Misses Street Forecasts Despite 224% Growth ↗
    Via Chartmill
    Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template ↗
    Via Chartmill
    Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q4 2025 Results with Revenue Beat and Wider-Than-Expected Loss ↗
    Via Chartmill
    News headline image
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Announces Participation in Upcoming Investor Conferences
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗
    This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗
    This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗
    This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗
    This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗
    This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment. 
    Via The Motley Fool
    News headline image
    Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗
    This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗
    This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax (SNDX) Q4 2025 Earnings Call Transcript ↗
    Syndax (SNDX) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Announces Participation in March Investor Conferences
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.